Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

The Post-Operative Pain pipeline market research report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for PostOperative Pain and features dormant and discontinued projects.

What are the key targets in the Post-Operative Pain pipeline market?

The key targets in the Post-Operative Pain pipeline market are Mu Type Opioid Receptor, Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, Sodium Channel Protein Type 2 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sodium Channel Protein Type 4 Subunit Alpha, Sodium Channel Protein Type 5 Subunit Alpha, and Sodium Channel Protein Type 8 Subunit Alpha. Mu Type Opioid Receptor has the highest number of pipeline products in the Post-Operative Pain pipeline market.

Post-Operative Pain pipeline market, by targets

Post-Operative Pain pipeline market, by targets

For more target insights, download a free report sample

What are the key MoA in the Post-Operative Pain pipeline market?

The key MoA in the Post-Operative Pain pipeline market are Mu Type Opioid Receptor Agonist, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Sodium Channel Protein Type 10 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, Sodium Channel Protein Type 1 Subunit Alpha Blocker, Sodium Channel Protein Type 2 Subunit Alpha Blocker, Sodium Channel Protein Type 3 Subunit Alpha Blocker, Sodium Channel Protein Type 4 Subunit Alpha Blocker, Sodium Channel Protein Type 8 Subunit Alpha Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker.

Post-Operative Pain pipeline market, by MoA

Post-Operative Pain pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key RoA in the Post-Operative Pain pipeline market?

The key RoA in the Post-Operative Pain pipeline market are Intravenous, Oral, Parenteral, Intravenous Bolus, Subcutaneous, Topical, Intramuscular, Sublingual, Intrathecal, and Ophthalmic. Intravenous has the highest number of pipeline products in the Post-Operative Pain pipeline market.

Post-Operative Pain pipeline market, by RoA

Post-Operative Pain pipeline market, by RoA

For more RoA insights, download a free report sample

What are the key molecule type in the Post-Operative Pain pipeline market?

The key molecule type in the Post-Operative Pain pipeline market are Small Molecule, Synthetic Peptide, Antisense Oligonucleotide, Aptamer, Gene Therapy, and Recombinant Protein. Small Molecule has the highest number of pipeline products in the Post-Operative Pain pipeline market.

Post-Operative Pain pipeline market, by molecule type

Post-Operative Pain pipeline market, by molecule type

For more molecule type insights, download a free report sample

What are the key companies in the Post-Operative Pain pipeline market?

The key companies in the Post-Operative Pain pipeline market are Jiangsu Hengrui Medicine Co Ltd, Allay Therapeutics Inc, Nanjing Delova Biotech Co Ltd, Neumentum Inc, Vivozon Inc, Altus Formulation Inc, Grunenthal GmbH, Hefei Cosource Pharmaceutical Inc, Heron Therapeutics Inc, InSitu Biologics LLC, and Lumosa Therapeutics Co Ltd. Jiangsu Hengrui Medicine Co Ltd Jiangsu Hengrui Medicine Co Ltd.

Post-Operative Pain pipeline market, by companies

Post-Operative Pain pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Key targets Mu Type Opioid Receptor, Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, Sodium Channel Protein Type 2 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sodium Channel Protein Type 4 Subunit Alpha, Sodium Channel Protein Type 5 Subunit Alpha, and Sodium Channel Protein Type 8 Subunit Alpha
Key MoA Mu Type Opioid Receptor Agonist, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Sodium Channel Protein Type 10 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, Sodium Channel Protein Type 1 Subunit Alpha Blocker, Sodium Channel Protein Type 2 Subunit Alpha Blocker, Sodium Channel Protein Type 3 Subunit Alpha Blocker, Sodium Channel Protein Type 4 Subunit Alpha Blocker, Sodium Channel Protein Type 8 Subunit Alpha Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker
Key RoA Intravenous, Oral, Parenteral, Intravenous Bolus, Subcutaneous, Topical, Intramuscular, Sublingual, Intrathecal, and Ophthalmic
Key molecule type Small Molecule, Synthetic Peptide, Antisense Oligonucleotide, Aptamer, Gene Therapy, and Recombinant Protein
Key companies Jiangsu Hengrui Medicine Co Ltd, Allay Therapeutics Inc, Nanjing Delova Biotech Co Ltd, Neumentum Inc, Vivozon Inc, Altus Formulation Inc, Grunenthal GmbH, Hefei Cosource Pharmaceutical Inc, Heron Therapeutics Inc, InSitu Biologics LLC, and Lumosa Therapeutics Co Ltd. Jiangsu Hengrui Medicine Co Ltd Jiangsu Hengrui Medicine Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acadia Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc
Adare Pharma Solutions
Algomedix Inc
Allay Therapeutics Inc
Altus Formulation Inc
AmacaThera Inc
Andros Pharmaceuticals Co Ltd
AngioChem Inc
Antibe Therapeutics Inc
Bayer AG
Beijing Join Chain Medicine Co Ltd
Benuvia Therapeutics Inc
Brainfarma Chemical and Pharmaceutical Industry SA
Cali Pharmaceuticals LLC
Camurus AB
Cara Therapeutics Inc
Cellix Bio Pvt Ltd
Chromocell Corp
Clexio Biosciences Ltd
Concentric Analgesics Inc
Cytogel Pharma LLC
Daewoong Pharmaceutical Co Ltd
Dompe Farmaceutici SpA
Douleur Therapeutics Inc
Eliem Therapeutics Inc
Ethismos Research Inc
Euclises Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
Eurofarma Laboratorios SA
Flexion Therapeutics Inc
Fujimoto Pharmaceutical Corp
G2GBIO Inc
Grunenthal GmbH
Guangdong Jiabo Pharmaceutical Co Ltd
Hana Pharm Co Ltd
Hefei Cosource Pharmaceutical Inc
Heron Therapeutics Inc
Hyloris Pharmaceuticals SA
IACTA Pharmaceuticals Inc
InSitu Biologics LLC
Insys Therapeutics Inc (Inactive)
InterK Peptide Therapeutics Ltd
Ionis Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Huatai Chenguang Pharmaceutical Co Ltd
Liquidia Technologies Inc
Lumosa Therapeutics Co Ltd
Luye Pharma Group Ltd
Medical Developments International Ltd
MedinCell SA
Mundipharma International Ltd
Nang Kuang Pharmaceutical Co Ltd
Nanjing Delova Biotech Co Ltd
Nanjing Heron Pharmaceutical Science and Technology Co Ltd
Neumentum Inc
Neurocarrus Inc
NeuroPn Therapeutics LLC
Nevakar Injectables Inc
Ocular Therapeutix Inc
Pacira BioSciences Inc
PainReform Ltd
Pharmazz Inc
PhytoHealth Corp
PolyPid Ltd
Revogenex Inc
RHNanopharmacuticals LLC
Rottapharm Biotech Srl
Sedor Pharmaceuticals LLC
Seelos Therapeutics, Inc.
Serina Therapeutics Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
Sonoran Biosciences Inc
Sotex Pharm Firm
Stragen New Molecules
Taiwan Liposome Co Ltd
Teikoku Pharma USA Inc
Theracaine LLC
Trevena Inc
Tris Pharma Inc
Vertex Pharmaceuticals Inc
Viatris Inc
Virpax Pharmaceuticals Inc
Vivozon Inc
Xgene Pharmaceutical Inc
Xigen SA
Yichang Humanwell Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Post-Operative Pain – Overview

Post-Operative Pain – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Post-Operative Pain – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post-Operative Pain – Companies Involved in Therapeutics Development

Post-Operative Pain – Drug Profiles

Post-Operative Pain – Dormant Projects

Post-Operative Pain – Discontinued Products

Post-Operative Pain – Product Development Milestones

Featured News & Press Releases

Mar 21, 2022: Cali Biosciences announces successful results in phase IIb study of long-acting ropivacaine (CPL-01) for non-opioid treatment of post-operative pain

Feb 02, 2022: Concentric analgesics forges important phase 3 clinical relationships for Vocacapsaicin, a non-opioid pain therapy targeting TRPV1 receptor

Feb 01, 2022: AcelRx Pharmaceuticals announces publication of clinical data on the use of sufentanil sublingual tablet during awake plastic surgery procedures

Jan 28, 2022: Jiangsu Enhua Pharmaceutical announcement on obtaining the notification of acceptance of application for marketing authorization of Oxelidine Fumarate Injection (TRV130)

Jan 27, 2022: AcelRx Pharmaceuticals announces publication of an article highlighting the utility of the sufentanil sublingual tablet in pain medicine procedures

Jan 12, 2022: AcelRx Pharmaceuticals announces publication of an editorial by an internationally recognized leader in opioid-sparing surgery highlighting the potential advantages of the sufentanil sublingual tablet in joint replacement surgery

Dec 15, 2021: AcelRx Pharmaceuticals announces publication of clinical data showing reduced hospital length of stay and reduced opioid utilization with use of sublingual sufentanil in total joint replacement surgery

Nov 22, 2021: Concentric Analgesics announces poster presentation of positive vocacapsaicin data from total knee arthroplasty phase 2 study at the 2021 American Academy of Hip and Knee Surgeons Annual Meeting

Nov 19, 2021: ASRA 2021: Cali Biosciences presents Phase IIa clinical data on CPL-01, a long-acting Ropivacaine

Nov 16, 2021: LT1001 formulation patent granted by JPO

Nov 15, 2021: Hyloris announces earlier than expected PDUFA date for Maxigesic IV

Nov 08, 2021: Pacira files lawsuit against eVenus for patent infringement

Nov 02, 2021: Pacira receives notice of allowance for new patent covering EXPAREL composition

Nov 01, 2021: Hyloris announces FDA acceptance of New Drug Application for Maxigesic IV in post-operative pain

Oct 28, 2021: InSitu Biologics INSB200 poster chosen “Best of Meeting” at American Society of Regional Anesthesia Pain Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Post-Operative Pain, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Companies, 2022 (Contd..4)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Post-Operative Pain – Pipeline by Acadia Pharmaceuticals Inc, 2022

Post-Operative Pain – Pipeline by AcelRx Pharmaceuticals Inc, 2022

Post-Operative Pain – Pipeline by Adare Pharma Solutions, 2022

Post-Operative Pain – Pipeline by Algomedix Inc, 2022

Post-Operative Pain – Pipeline by Allay Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Altus Formulation Inc, 2022

Post-Operative Pain – Pipeline by AmacaThera Inc, 2022

Post-Operative Pain – Pipeline by Andros Pharmaceuticals Co Ltd, 2022

Post-Operative Pain – Pipeline by AngioChem Inc, 2022

Post-Operative Pain – Pipeline by Antibe Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Bayer AG, 2022

Post-Operative Pain – Pipeline by Beijing Join Chain Medicine Co Ltd, 2022

Post-Operative Pain – Pipeline by Benuvia Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Brainfarma Chemical and Pharmaceutical Industry SA, 2022

Post-Operative Pain – Pipeline by Cali Pharmaceuticals LLC, 2022

Post-Operative Pain – Pipeline by Camurus AB, 2022

Post-Operative Pain – Pipeline by Cara Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Cellix Bio Pvt Ltd, 2022

Post-Operative Pain – Pipeline by Chromocell Corp, 2022

Post-Operative Pain – Pipeline by Clexio Biosciences Ltd, 2022

Post-Operative Pain – Pipeline by Concentric Analgesics Inc, 2022

Post-Operative Pain – Pipeline by Cytogel Pharma LLC, 2022

Post-Operative Pain – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Post-Operative Pain – Pipeline by Dompe Farmaceutici SpA, 2022

Post-Operative Pain – Pipeline by Douleur Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Eliem Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Ethismos Research Inc, 2022

Post-Operative Pain – Pipeline by Euclises Pharmaceuticals Inc, 2022

Post-Operative Pain – Pipeline by Eupraxia Pharmaceuticals Inc, 2022

Post-Operative Pain – Pipeline by Eurofarma Laboratorios SA, 2022

Post-Operative Pain – Pipeline by Flexion Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Fujimoto Pharmaceutical Corp, 2022

Post-Operative Pain – Pipeline by G2GBIO Inc, 2022

Post-Operative Pain – Pipeline by Grunenthal GmbH, 2022

Post-Operative Pain – Pipeline by Guangdong Jiabo Pharmaceutical Co Ltd, 2022

Post-Operative Pain – Pipeline by Hana Pharm Co Ltd, 2022

Post-Operative Pain – Pipeline by Hefei Cosource Pharmaceutical Inc, 2022

Post-Operative Pain – Pipeline by Heron Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Hyloris Pharmaceuticals SA, 2022

Post-Operative Pain – Pipeline by IACTA Pharmaceuticals Inc, 2022

Post-Operative Pain – Pipeline by InSitu Biologics LLC, 2022

Post-Operative Pain – Pipeline by Insys Therapeutics Inc (Inactive), 2022

Post-Operative Pain – Pipeline by InterK Peptide Therapeutics Ltd, 2022

Post-Operative Pain – Pipeline by Ionis Pharmaceuticals Inc, 2022

Post-Operative Pain – Pipeline by iX Biopharma Ltd, 2022

Post-Operative Pain – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Post-Operative Pain – Pipeline by Jiangsu Huatai Chenguang Pharmaceutical Co Ltd, 2022

Post-Operative Pain – Pipeline by Liquidia Technologies Inc, 2022

Post-Operative Pain – Pipeline by Lumosa Therapeutics Co Ltd, 2022

Post-Operative Pain – Pipeline by Luye Pharma Group Ltd, 2022

Post-Operative Pain – Pipeline by Medical Developments International Ltd, 2022

Post-Operative Pain – Pipeline by MedinCell SA, 2022

Post-Operative Pain – Pipeline by Mundipharma International Ltd, 2022

Post-Operative Pain – Pipeline by Nang Kuang Pharmaceutical Co Ltd, 2022

Post-Operative Pain – Pipeline by Nanjing Delova Biotech Co Ltd, 2022

Post-Operative Pain – Pipeline by Nanjing Heron Pharmaceutical Science and Technology Co Ltd, 2022

Post-Operative Pain – Pipeline by Neumentum Inc, 2022

Post-Operative Pain – Pipeline by Neurocarrus Inc, 2022

Post-Operative Pain – Pipeline by NeuroPn Therapeutics LLC, 2022

Post-Operative Pain – Pipeline by Nevakar Injectables Inc, 2022

Post-Operative Pain – Pipeline by Ocular Therapeutix Inc, 2022

Post-Operative Pain – Pipeline by Pacira BioSciences Inc, 2022

Post-Operative Pain – Pipeline by PainReform Ltd, 2022

Post-Operative Pain – Pipeline by Pharmazz Inc, 2022

Post-Operative Pain – Pipeline by PhytoHealth Corp, 2022

Post-Operative Pain – Pipeline by PolyPid Ltd, 2022

Post-Operative Pain – Pipeline by Revogenex Inc, 2022

Post-Operative Pain – Pipeline by RHNanopharmacuticals LLC, 2022

Post-Operative Pain – Pipeline by Rottapharm Biotech Srl, 2022

Post-Operative Pain – Pipeline by Sedor Pharmaceuticals LLC, 2022

Post-Operative Pain – Pipeline by Seelos Therapeutics, Inc., 2022

Post-Operative Pain – Pipeline by Serina Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Shijiazhuang Yiling Pharmaceutical Co Ltd, 2022

Post-Operative Pain – Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022

Post-Operative Pain – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022

Post-Operative Pain – Pipeline by SiteOne Therapeutics Inc, 2022

Post-Operative Pain – Pipeline by Sonoran Biosciences Inc, 2022

Post-Operative Pain – Pipeline by Sotex Pharm Firm, 2022

Post-Operative Pain – Pipeline by Stragen New Molecules, 2022

Post-Operative Pain – Pipeline by Taiwan Liposome Co Ltd, 2022

Post-Operative Pain – Pipeline by Teikoku Pharma USA Inc, 2022

Post-Operative Pain – Pipeline by Theracaine LLC, 2022

Post-Operative Pain – Pipeline by Trevena Inc, 2022

Post-Operative Pain – Pipeline by Tris Pharma Inc, 2022

Post-Operative Pain – Pipeline by Vertex Pharmaceuticals Inc, 2022

Post-Operative Pain – Pipeline by Viatris Inc, 2022

Post-Operative Pain – Pipeline by Virpax Pharmaceuticals Inc, 2022

Post-Operative Pain – Pipeline by Vivozon Inc, 2022

Post-Operative Pain – Pipeline by Xgene Pharmaceutical Inc, 2022

Post-Operative Pain – Pipeline by Xigen SA, 2022

Post-Operative Pain – Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022

Post-Operative Pain – Dormant Projects, 2022

Post-Operative Pain – Dormant Projects, 2022 (Contd..1)

Post-Operative Pain – Dormant Projects, 2022 (Contd..2)

Post-Operative Pain – Dormant Projects, 2022 (Contd..3)

Post-Operative Pain – Dormant Projects, 2022 (Contd..4)

Post-Operative Pain – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Post-Operative Pain, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Post-Operative Pain pipeline market?

    The key targets in the Post-Operative Pain pipeline market are Mu Type Opioid Receptor, Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, Sodium Channel Protein Type 2 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sodium Channel Protein Type 4 Subunit Alpha, Sodium Channel Protein Type 5 Subunit Alpha, and Sodium Channel Protein Type 8 Subunit Alpha. Mu Type Opioid Receptor has the highest number of pipeline products in the Post-Operative Pain pipeline market.

  • What are the key MoA in the Post-Operative Pain pipeline market?

    The key MoA in the Post-Operative Pain pipeline market are Mu Type Opioid Receptor Agonist, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Sodium Channel Protein Type 10 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, Sodium Channel Protein Type 1 Subunit Alpha Blocker, Sodium Channel Protein Type 2 Subunit Alpha Blocker, Sodium Channel Protein Type 3 Subunit Alpha Blocker, Sodium Channel Protein Type 4 Subunit Alpha Blocker, Sodium Channel Protein Type 8 Subunit Alpha Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker.

  • What are the key RoA in the Post-Operative Pain pipeline market?

    The key RoA in the Post-Operative Pain pipeline market are Intravenous, Oral, Parenteral, Intravenous Bolus, Subcutaneous, Topical, Intramuscular, Sublingual, Intrathecal, and Ophthalmic. Intravenous has the highest number of pipeline products in the Post-Operative Pain pipeline market.

  • What are the key molecule type in the Post-Operative Pain pipeline market?

    The key molecule type in the Post-Operative Pain pipeline market are Small Molecule, Synthetic Peptide, Antisense Oligonucleotide, Aptamer, Gene Therapy, and Recombinant Protein. Small Molecule has the highest number of pipeline products in the Post-Operative Pain pipeline market.

  • What are the key companies in the Post-Operative Pain pipeline market?

    The key companies in the Post-Operative Pain pipeline market are Jiangsu Hengrui Medicine Co Ltd, Allay Therapeutics Inc, Nanjing Delova Biotech Co Ltd, Neumentum Inc, Vivozon Inc, Altus Formulation Inc, Grunenthal GmbH, Hefei Cosource Pharmaceutical Inc, Heron Therapeutics Inc, InSitu Biologics LLC, and Lumosa Therapeutics Co Ltd. Jiangsu Hengrui Medicine Co Ltd Jiangsu Hengrui Medicine Co Ltd.

Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.